Full-Life Technologies, a fully integrated global radiotherapeutics company announced the completion of $63.3 million financing, comprised of $47.3 million in Series B equity financing and $16 million in loan facilities.
Read also – Khazanah and CGC Digital Announce Strategic Investment in Funding Societies
The financing will advance development of the Full-Life Technologies’s radiopharmaceutical pipeline and manufacturing capabilities, as well as optimize its proprietary discovery platform, UniRDC™. With completion of such financing, Full-Life has secured more than $110 million funding since its inception in August 2021, including equity financing, loan facilities, and government subsidies.
Read also – Cloud Security Platform Orca Security lays off 15% of workforce
The $47.3 million Series B equity financing was co-led by Prosperity7 Ventures and an undisclosed healthcare specialist investor, along with new investors Sky9 Capital, Summer Capital, and GuanghuaWutong Fund, as well as existing shareholders Chengwei Capital, HongShan, and Junson Capital. The $16 million loan facilities, secured in conjunction with the Series B equity financing, provide Full-Life with a flexible financing solution for the Company’s pipeline development and construction of the radiopharmaceutical manufacturing plant in Belgium.
Read also – Aqua Security Closes $60M Additional Funding at a Valuation Above $1B
“Cancer remains a formidable global challenge, causing immense suffering and loss,” said Aysar Tayeb, Executive Managing Director of Prosperity7 Ventures. “Full-Life is dedicated to addressing this issue within the field of Radionuclide Drug Conjugates (RDC) by leveraging its exceptional vector and linker design capabilities, as well as its expertise in radionuclides. Through its UniRDC™ platform, Full-Life has the potential to extend its therapeutic indications to a wider range of cancers. We eagerly anticipate the future advancements of Full-Life, as it strives to deliver differentiated and superior solutions that will significantly improve the outcomes and quality of life for cancer patients.”
Read also – Robin AI Raises $26M Series B Funding led by Temasek
“The financing reflects strong support from our new and existing investors of our strategy and faith in the significant progress we have made in just over two years to build a fully integrated radiopharmaceutical company,” said Julie Wu, Chief Financial Officer of Full-Life. “The funding will support our evolution into a clinical-stage company, the advancement of our pipeline programs, and the construction of a Good Manufacturing Practices (GMP) manufacturing facility.”
Read also – Micoworks Raises Approximately US$24.5M to Accelerate Global Business Expansion
About Full-Life Technologies
Full-Life Technologies Limited is a fully integrated global radiotherapeutics company with operations in Belgium, Germany, and China. We seek to own the entire value chain for radiopharmaceutical research & development, production & commercialization in order to deliver clinical impact for patients. The Company plans to attack core issues affecting radiopharmaceuticals today through innovative research that targets the treatments of tomorrow. We are comprised of a team of fast-moving entrepreneurs and scientists with a demonstrated track record in the life sciences, as well as radioisotope research and clinical development.
Read also – Singapore-based Cumulus Encrypted Storage System Raises $8M Series A Funding
